Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Nitric Oxide Donors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Nitric Oxide Donors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Nitrous oxide (NO) is a ubiquitous signaling molecule and is present virtually in all tissues in the human body and plays a vital role in many physiological processes like regulating vessel homeostasis, prevention of thrombosis, role in platelet activation, inflammatory processes, and wound healing processes. NO released by the body is responsible for making the penis erect during sexual intercourse. Also, before childbirth, NO released by the infant’s vessels is responsible for preventing the closure of the ductus arteriosus. NO is produced endogenously using L-arginine in the wall of the blood vessels as a substrate of low concentration by the enzyme NO synthases. Dysfunctions in NO production and regulation have also been associated with chronic lung infections, especially in cystic fibrosis (CF) patients, wound infections, vascular diseases like ischaemic heart diseases, angina pectoris, hypertension, etc. Moreover, NO released in the eyes has a role to play in draining out the aqueous humor facilitated by PGF2α plays a significant role in the pathophysiology of Glaucoma. Companies are trying to find new and novel molecules to prevent and cure these diseases. The development and launch of newer products by the market players will significantly enhance the revenue of the Nitric Oxide Donors market over the forecast years. For instance, according to a research article, angina is the most common symptom of ischaemic heart disease, and approximately 9 million in 2022 in the USA have symptoms of angina.
A number of these inhibitors are in the market while many are in ongoing clinical trials. 22 companies have various products in their pipelines with 21 products in various stages of clinical trials. 2 products are in Phase 4, 4 products are in Phase 3, 13 products are in Phase 2 and 1 product is in Phase 1 of the clinical trials.
Approved molecules
Drugs in Pipeline
Clinical Activity and Developments of Nitric Oxide Donors
As of June 2023, 22 companies have approximately 21 products for 104 diseases. For these diseases, more than 19 trials are being conducted by the players globally. For instance,
|
Molecule name |
Number of studies |
|
Vascana (nitroglycerin) |
10 |
|
cimlanod (BMS986231) |
10 |
|
Rectiv (nitroglycerin) |
8 |
|
B244 topical |
7 |
|
BiDil (hydralazine isosorbide dinitrate) |
5 |
Drugs like Rectiv (nitroglycerin) and BiDil (hydralazine and isosorbide dinitrate) are commercially available NO donors are used in the treatment of various indications like Angina Pectoris and Ischaemic Heart Diseases. NO donors are used in many other indications like treating Erectile Dysfunction (ED), Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension in newborns, and others. However, the most use of NO donors is for the treatment of angina pectoris as a vasodilator. According to the Department of Health, every year, about 697,000 people die because of heart disease in the USA, wherein 382,820 deaths are due to coronary heart disease (CAD).
According to the British Heart Foundation Report 2023, CHD death rates are highest in Scotland and the North of England. There are 2.3 million people in the UK living with CHD, and approximately 66,000 deaths occur every year, with an estimated 1 death every 8 minutes. An estimated more than 7.6 million UK people will be living with Cardiovascular Disease (CVD) in 2021. Also, it is estimated that around 1.4 million people alive in the UK have survived a heart attack, and one patient is admitted to the hospital every 5 minutes due to a heart attack. There is an opportunity for the market players globally due to the rising prevalence of these diseases.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Rectiv (nitroglycerin), BiDil (hydralazine/isosorbide dinitrate), Glytrin (Glyceryl Trinitrate) are some of the Nitric Oxide Donors approved by the FDA.
These are being used in various indications like Coronary Artery Disease (CAD), Pulmonary Hypertension (PH), Angina Pectoris, Erectile dysfunction and others
MediQuestpharma (USA), BMS (USA), Kyowa Kirin Co., Ltd (Japan), Endo Pharmaceuticals Inc. (USA) and AOBiome (USA) are some of the major market players for Nitric Oxide Donors.
Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market and changing lifestyles leading to cardiovascular and ophthalmic disorders are the key opportunities for Nitric Oxide Donors in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.